Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and pharmacological treatments without systematic search methodology
PubMed 40873858 · doi:10.2147/DDDT.S542000
What was done
This narrative review summarizes the current understanding of androgenetic alopecia pathogenesis (including genetic predisposition, androgen metabolism, inflammation, fibrosis, and impaired energy metabolism) and reviews the mechanisms of action and clinical efficacy of pharmacological therapies.
What was found
The abstract reports no numerical data, trial counts, or statistical results. It states that finasteride and minoxidil remain the only two widely recognized and legally approved therapeutic options globally, amid ongoing development of novel mechanistic agents.
Why it matters
It provides a consolidated theoretical and clinical overview of current and emerging drug targets for androgenetic alopecia management.
Limits
The paper is a non-systematic narrative review providing no quantitative synthesis, sample sizes, or search protocol. No primary human outcome data are reported in the abstract.
Cited by
- supports Minoxidil acts as a hair growth stimulant but does not attenuate or prevent hair follicle miniaturization caused by DHT.